Jane Street’s Corvus Pharmaceuticals CRVS Stock Holding History

Jane Street’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.09M	Sell	140,200 -77,600	-36%	-$1.08M	﹤0.01%	5080
2026 Q1	$3.19M	Buy	217,800 +179,100	+463%	+$2.86M	﹤0.01%	4240
2025 Q4	$298K	Buy	+38,700	New	+$305K	﹤0.01%	8853
2025 Q2	–	Sell	-21,300	Closed	-$67.7K	–	9788
2025 Q1	$67.7K	Sell	21,300 -141,000	-87%	-$664K	﹤0.01%	8931
2024 Q4	$868K	Buy	+162,300	New	+$1.21M	﹤0.01%	5649
2021 Q4	–	Sell	-342,000	Closed	-$1.66M	–	10153
2021 Q3	$1.66M	Buy	+342,000	New	+$1.01M	﹤0.01%	4872

Other funds holding CRVS

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Jane Street's CRVS Position: Q2 2026 in Review

Jane Street sold out of Corvus Pharmaceuticals (CRVS) in Q2 2026, closing a stake of 44,473 shares — an estimated $617K sold.

Jane Street first reported a position in CRVS in Q3 2021 and held it in 11 quarters. The position peaked at $2.91M in Q4 2025. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

Jane Street reported no remaining Corvus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Jane Street sold 44,473 Corvus Pharmaceuticals shares in Q2 2026, an estimated $617K.
Jane Street first reported a position in Corvus Pharmaceuticals in Q3 2021 and held it in 11 quarters.
Jane Street's Corvus Pharmaceuticals position peaked at $2.91M in Q4 2025.
174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.